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A B S T R A C T
Ocular bioavailability after eye drops administration is an important, but rarely determined, pharmacokinetic
parameter. In this study, we measured the pharmacokinetics of a cocktail of three beta blockers after their
topical administration into the albino rabbit eye. Samples from aqueous humour were analysed with LC-MS/MS.
The pharmacokinetic parameters were estimated using compartmental and non-compartmental analyses. The
ocular bioavailability was covering broad range of values: atenolol (0.07 %), timolol (1.22%, 1.51%) and be-
taxolol (3.82%, 4.31%). Absolute ocular bioavailability presented a positive trend with lipophilicity and the
values showed approximately 60-fold range. The generated data enhances our understanding for ocular phar-
macokinetics of drugs and may be utilized in pharmacokinetic model building in ophthalmic drug development.
1. Introduction
Topical administration is currently the most common route for the
treatment of diseases affecting the anterior part of the eye. Ocular
bioavailability after topical administration is stated to be less than 10
%, but bioavailability has been determined only for four compounds in
rabbits and not at all in humans. Several pre-corneal factors, such as the
drainage of excess fluid, normal tear turnover and systemic absorption
through conjunctiva remove the drug from the ocular surface de-
creasing the drug absorption into intraocular tissues
(Himmelstein et al., 1978; Lee and Robinson, 1979). Flow of drug so-
lution into the nasolacrimal duct leads to further systemic absorption
from the nasal mucosa and gastrointestinal tract (Himmelstein et al.,
1978; Lee and Robinson, 1979; Urtti and Salminen, 1993).
The main ocular absorption routes after topical administration are
across the cornea and conjunctiva (Fig. 1). After corneal absorption the
drug permeates into the aqueous humour and further into the iris and
ciliary body followed by elimination to the systemic circulation. Drug
may also be eliminated by aqueous humour turnover into the trabecular
meshwork and Schlemm's canal or distribute into the lens. Transfer of
drug towards the vitreous humour is hindered by the aqueous humour
flow in the posterior-to-anterior direction (Maurice and
Mishima, 1984). Drug may also absorb into the eye across the con-
junctiva and sclera and then distribute further into the iris and ciliary
body (Ahmed et al., 1987; Ahmed and Patton, 1985). Most of con-
junctival drug permeation leads to systemic circulation instead of in-
traocular distribution.
The corneal permeation is the most important ocular absorption
route for lipophilic drugs (Doane et al., 1978; Schoenwald, 1987). The
corneal epithelium is the main penetration barrier in the cornea
(Lach et al., 1983; Schoenwald, 1987; Schoenwald, 1990;
Schoenwald and Huang, 1983). Trans-conjunctival drug absorption
contributes very little to drug concentrations in the aqueous humour
(Ahmed et al., 1987; Ahmed and Patton, 1985) which is the main site in
the assessment of topical ocular bioavailability.
The absolute ocular bioavailability is the ratio of the dose-
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normalized areas under the concentration curve (AUC) in aqueous
humour after topical and intracameral administration, respectively. In
the latter case, the drug is directly injected into the anterior chamber
and this situation represents 100% bioavailability.
In the present study we determined the topical pharmacokinetics for
three anti-glaucoma drugs, atenolol, timolol, and betaxolol that re-
present a range of lipophilicity values (Fig. 2). These beta-blockers were
applied topically as a cocktail on rabbit eyes, aqueous humour drug
concentrations were quantified and pharmacokinetic parameters were
determined including absolute ocular bioavailability (with intracameral
pharmacokinetic data from our previous study (Fayyaz et al., 2019)).
2. Material and Method
2.1. Animal experiments
Animals - Sixteen male albino New Zealand rabbits, age 3–6 months
and weight 2.8–3.2 kg, were used in the experiments. The animals were
housed in a temperature and humidity-controlled environment with a
12/12 light/dark cycle. The animals were individually housed and fed a
normal diet. All rabbits underwent an ocular examination before being
accepted into experiments. Animals were handled in accordance with
the statement of the Animals in Research Committee of the ARVO
(Association for Research in Vision and Ophthalmology, Rockville,
Maryland, USA) and all animal experiments were approved by the na-
tional Animal Experiment Board of Finland.
Topical application of the beta-blocker cocktail was performed fol-
lowed by a collection of a single aqueous humour sample from each
animal. The sampling times were 5, 10, 20, 30, 60, 120, 180 and
240 min, and the number of eyes at each time point were four (n=4).
The cocktail containing 20 mM atenolol (USP reference standard,
Sigma), 10 mM betaxolol hydrochloride (USP reference standard,
Sigma) and 10 mM timolol maleate (USP reference standard, Sigma) in
phosphate-buffered saline (DPBS, Thermofisher Scientific) (pH adjusted
to 7.4; 322 mOsm/kg) was administered onto the upper cornea-scleral
limbus of both eyes (25 µL/eye) in each rabbit. The animals were sa-
crificed by injecting into the marginal ear vein a lethal dose of pento-
barbital (Mebunat vet 60 mg/mL; Orion Pharma, Finland) and aqueous
humour was aspirated from anterior chamber. All samples were cooled
on ice following storage at -80 °C until analysis.
2.2. Analysis of aqueous humour samples
Standards (0.1 – 5000 nM) were prepared from the beta blocker
mixture in PBS and diluted with a solution containing 20% porcine
aqueous humour and 80% PBS. Atenolol-d7 (Toronto Research
Chemicals, Canada), betaxolol-d5 (Toronto Research Chemicals,
Canada) and Rac timolol-d5 Maleate (Toronto Research Chemicals,
Canada) were used as internal standards (ISTDs). The 1 mg/mL stock
solutions were first prepared in DMSO and then diluted to ISTD solution
containing 50 ng/mL atenolol-d7, 5 ng/mL betaxolol-d5, 5 ng/mL rac
timolol-d5 maleate and 1% formic acid in acetonitrile.
Equal volumes (50 µL) of standard solutions and ISTD solution were
mixed by vortexing for 10 sec. After 15 min precipitation step the
standards were centrifuged (5 min, +4°C, 13000 rpm) and supernatant
was collected for LC-MS analysis. Quality controls (2.5, 25, 250 and
1500 nM) in triplicates were prepared in similar manner. Aqueous
humour samples were first diluted 1:5 with PBS and then ISTD solution
Fig. 1. Ocular pharmacokinetics after topical
administration. A: Absorption and elimination
pathways after topical drug administration: 1)
corneal absorption; 2) conjunctival absorption;
3) clearance through nasolacrimal duct; 4)
elimination to trabecular meshwork; 5) dis-
tribution to iris-ciliary body; 6) distribution to
lens. B: Anatomy of the eye. (https://www.
publicdomainpictures.net/en/view-image.
php?image=130389&picture= medical-eye).
Fig. 2. The chemical structures of atenolol,
timolol and betaxolol with the corresponding
logarithm of the octanol-water distribution
coefficient at pH 7.4 (log D7.4) values and pKa
values (calculated using ACD/labs, version
2020.1.1, Advanced Chemistry Development,
Inc. Toronto, Canada) at pH 7.4 the relative
abundance for ionized fraction versus union-
ized is > 99/1 for the three drugs.
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was added. Thereafter, the procedure was similar to the handling of
standards. The standards, samples and quality controls were analysed
with LC-MS/MS (Agilent 1290 liquid chromatograph and Agilent 6495
triple quadrupole mass spectrometer, Agilent Technologies Inc., USA)
using protocol described earlier (Fayyaz et al., 2019).
The calibration curve was prepared as duplicate and calculated as a
mean of two injections using 9–11 concentration levels of total 14 le-
vels. Calibration curves had 85 - 115 % mean accuracies. QC samples
were 90 - 110% of the nominal concentrations with imprecision below
10%.
2.3. Pharmacokinetic analysis
Compartmental analysis was performed using Phoenix WinNonlin
(build 8.1, Certara L.P.). Mean concentration data was analysed using
one- and two-compartment models with first-order absorption kinetics.
Akaike's information criterion and visual inspection of the plot of ob-
served and predicted concentrations versus time were used to select the
best compartmental model. Curve fitting was performed using three
different weighting schemes: uniform, 1/predicted concentration (1/
Yhat) and 1/(predicted concentration)2 (1/Yhat2). Coefficient of var-
iation (CV%) of estimated parameters and residual plots were utilized
for choosing the best weighting scheme within the same compartmental
model. AUC from time zero to infinity (AUCinf,Top), the maximal con-
centration (Cmax,Top), time at the maximal concentration (tmax,Top) and
elimination half-life (t1/2,Top) were obtained following topical applica-
tion of the three drugs. Non-compartmental analysis was also per-
formed using mean concentrations and the linear trapezoidal rule
(Supplementary data Table S3).
Aqueous humour bioavailability for the three beta-blockers was











where Top and IC refer to topical and intracameral administration,
respectively. Data for IC administration were taken from our previous
study (Fayyaz et al., 2019).
3. Results
3.1. Topical pharmacokinetic parameters
The mean aqueous humour concentration data was fitted for the
three beta blockers. One-compartment model was the best structural
model, using the 1/Yhat2 weighting model for all three drugs. The final
model estimated concentrations are presented in Fig. 3 together with
the observed data. The more lipophilic compounds betaxolol and ti-
molol achieved higher aqueous humour concentrations than the more
hydrophilic compound atenolol. Five measured aqueous humour con-
centrations across the three drugs were excluded from the
pharmacokinetics analysis since they were considered to be outliers
(Supplementary data Table S1). The pharmacokinetic parameters esti-
mated from the compartmental analysis are listed in Table 1.
The AUCinf,Top of betaxolol was 12 and 2 times higher than the dose-
normalized values of atenolol and timolol, respectively and similar
trends are seen for Cmax,Top (Table 1). The half-life of atenolol in the
aqueous humour was 3–5 times longer than the half-lives of timolol and
betaxolol.
3.2. Absolute topical bioavailabilities
The dose-normalized comparison of the concentration profiles of the
three beta-blockers after topical and intracameral administration in
rabbit eye (Fayyaz et al., 2019) is presented in Fig. 4.
Drug bioavailability values in aqueous humour from our topical
pharmacokinetic study and the previous intracameral study
(Fayyaz et al., 2019) are presented in Table 2. The order of bioavail-
abilities is betaxolol> timolol > atenolol based on both compartmental
and non-compartmental analyses. The results show a substantial 55–62-
fold difference between the bioavailability of betaxolol (3.82%, 4.31%)
and atenolol (0.07%).
4. Discussion
A cocktail approach was used to determine the ocular exposure of
three drugs after topical administration. This approach reduces the
number of animals needed and reduces variability arising due to inter-
individual differences and analytical factors. Previously, we have used
the same approach to investigate the intracameral pharmacokinetics of
the same drug set in the rabbit eye (Fayyaz et al., 2019). The combi-
nation of both studies allows us to determine the absolute bioavail-
ability in aqueous humour for betaxolol, timolol and atenolol. Both
compartmental analysis and non-compartmental analysis were carried
out and yielded similar bioavailability values showing robust results.
Ocular bioavailability is typically determined for aqueous humour,
even though ciliary body is the target tissue for beta blocker anti-
glaucoma drugs. The reason is that bioavailability calculation requires a
direct injection into the investigated tissue for the determination of the
drug clearance from the tissue. This is not feasible for iris-ciliary body,
while it is possible for aqueous humour after intracameral injection.
Bioavailability is critically important parameter that provides useful
information on the ocular exposure of different drugs and drugs in
different formulations. Bioavailability shows the drug fraction absorbed
in aqueous humour, while the concentration curves in the aqueous
humour after topical administration are not only affected by absorption
but also by the clearance from the aqueous humour (CLIC in Table 2,
Fig. 4). Unfortunately, there are only a few studies that report phar-
macokinetics for both topical and intracameral administration of oph-
thalmic drugs (Ling and Combs, 1987; Tang-Liu et al., 1984;
Yamamura et al., 1999) allowing the determination of absolute drug
Fig. 3. Aqueous humour concentration-time profiles in rabbits after topical application of atenolol (dose = 500 nmol), timolol (dose = 250 nmol) and betaxolol
(dose = 250 nmol) in a cocktail. Each circle represents the mean concentration± standard error of the mean (n = 3–4). The best fits based on one-compartmental
first-order pharmacokinetic model are represented by the dashed line.
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bioavailability to the aqueous humour. Compiling our data with these
literature studies shows a wide range of ocular bioavailabilities ranging
from 0.07 to 10 % (Fig. 5). A positive trend of ocular bioavailability can
be seen with lipophilicity (log D7.4) as lipophilic compounds tend to
have a higher ocular bioavailability than more hydrophilic compounds
(Fig. 5) presumably due to the higher permeability in the cornea
(Kidron et al., 2010). Plotting aqueous humour pharmacokinetic para-
meters (Cmax,Top, AUCinf,Top, bioavailability) against corneal perme-
ability or cornea/conjunctiva permeability ratios in rabbit (Wang et al.,
1991) results in excellent correlation (Supplementary data Figure S3
and S4). Several studies have pointed out the importance of drug li-
pophilicity on corneal permeability (Chien et al., 1990; Lach et al.,
1983; Rusinko et al., 2007; Schoenwald, 1987; Schoenwald and
Huang, 1983; Wang et al., 1991), but it is important to note that ocular
bioavailability of lipophilic drugs is also limited by their fast penetra-
tion across the conjunctiva to the systemic circulation (Ramsay et al.,
2018; Wang et al., 1991). Corneal penetration may also be influenced
by other factors such as drug ionization, molecular size and medium
(pH, osmotic pressure, other components) (Brechue and Maren, 1993;
Kidron et al., 2010; Pescina et al., 2015).
Since bioavailability data for other beta-blockers are missing, we
compared the dose-normalized AUCinf,Top and Cmax,Top values of drug
sets in which timolol was investigated (Araie et al., 1982; Huang et al.,
Table 1
Compartmental analysis of aqueous humour concentrations after topical administration of atenolol (dose = 500 nmol and dose-normalized valuesa), timolol
(dose = 250 nmol) and betaxolol (dose = 250 nmol) in rabbits. SE = standard error of the estimates.
Drug Dose (nmol) AUCinf,Top ± SE (min*nmol/ mL) Cmax,Top ± SE (nmol/mL) tmax,Top± SE (min) t1/2,Top± SE (min)
Atenolol 500 48.6±15.8 0.22± 0.06 31.6± 15.5 130.4±78.4
250a 24.3a 0.11a
Timolol 250 152±14 1.99± 0.20 17.3± 3.7 38.9± 2.9
Betaxolol 250 280±47.8 4.07± 0.69 21.9± 5.1 27.3± 3.3
Fig. 4. Aqueous humour concentration-time profiles of atenolol, timolol and betaxolol after topical and intracameral administration. The concentrations have been
normalized to the dose of 250 nmol.
Table 2
Aqueous humour bioavailability of atenolol, timolol and betaxolol using compartmental and non-compartmental analyses (CA: compartmental analysis, NCA: non-
compartmental analysis).
Topical administration Intracameral administrationa Bioavailability
Drugs Dose AUCinf,Top± SE (min*nmol/ mL) Dose CLIC± SE VdIC± SE AUCinf,IC ± SE (min*nmol/ mL) (%)
(nmol) CA NCA (nmol) (µL/min) (µL) CA NCA CA NCA
Atenolol 500 48.6± 15.8 39.2 5 6.44±0.83 687±140 691±141 545 0.07 0.07
Timolol 250 152±14 151 5 19.3±2.66 937±172 248±52 199 1.22 1.51
Betaxolol 250 280±47.8 252 5 32.2±4.10 1421 ± 236 146±27 117 3.82 4.31
VdIC: Volume of distribution after intracameral injection
CLIC: Clearance after intracameral injection
a Fayyaz et al., 2019
Fig. 5. Bioavailability versus log D7.4 of ophthalmic topical drugs in rabbit eyes
of six drugs i.e. atenolol, timolol and betaxolol from present study (blue dia-
monds, bioavailability determined using non-compartmental analysis) and ke-
torolac (Ling and Combs, 1987), flurbiprofen (Tang-Liu et al., 1984), timolol
and tilisolol (Yamamura et al., 1999) (bioavailability determined from non-
compartmental analysis) from the literature (red squares).
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1983; Ohtori et al., 1998; Ros et al., 1980; Schmitt et al., 1981;
Yamamura et al., 1999). We compared the beta-blocker/timolol para-
meter ratios within each study (Supplementary data Table S2 and
Figure S1) and observed higher AUCinf,Top ratio for befunolol
(Araie et al., 1982), but not for tilisolol (Yamamura et al., 1999), even
though both compounds are more lipophilic than timolol (Supplemen-
tary data Figure S1). Based on these pharmacokinetic parameters, we
cannot conclude that higher lipophilicity necessarily results in in-
creased drug concentrations in the aqueous humour because clearance
from aqueous humour through iris-ciliary body to systemic circulation
(Fig. 1) is also faster for more lipophilic compounds (Fayyaz et al.,
2019). The faster clearance and shorter half-lives are also shown in
Table 2 and Fig. 4. In order to quantitatively understand topical ocular
pharmacokinetics, determination of bioavailability is essential.
The data variability amongst topical ocular drug studies is sig-
nificant and this supports using a cocktail approach that allows gen-
eration of reliable and comparable values within the drug set.
Moreover, the validity of this approach is proved when showing that
one of the cocktail drugs, timolol, presents comparable pharmacoki-
netics to the ones reported in the literature (Supplementary data Figure
S2). Even in our study some drug concentrations at 5 min were un-
expectedly high compared with the later time points, especially for
atenolol (Fig. 3, Supplementary data Table S1). We cannot exclude the
possibility that these aqueous humour samples contained drug traces
from tear fluid even though we tried to avoid the cross-contamination
of the aqueous humour samples by careful sampling. In any case, these
early samples have a minimal contribution to the values of AUCinf,Top
and bioavailability, thereby they do not have any influence on our
conclusions.
The present data generated for atenolol, timolol and betaxolol can
be used to aid further studies with these drugs. Exact values for ocular
bioavailability can be useful aid in the development of new drug de-
livery systems (Subrizi et al., 2019).
Conclusion
Three beta blockers were administered topically and their ocular
pharmacokinetics were evaluated. Absolute bioavailability of atenolol,
timolol and betaxolol was quantitated in aqueous humour. The data
shows broad, about 60-fold, range of bioavailability for topical beta
blocking agents. The outcomes of this study is for improved under-
standing on ocular pharmacokinetics and may inform ophthalmic to-
pical drug dosing and drug development.
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